ARFIP2

Across TCGA pan-cancer cohorts, ARFIP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARFIP2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARFIP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARFIP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where ARFIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.751	0.914	.005	14	view →
LUAD	OS	Quartile	II,III,IV	0.366	0.922	.004	13	view →
UCEC	DFS	Median	All	0.953	0.858	.032	6	view →
HNSC	DFS	Tertile	IV	0.866	0.569	.023	5	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	5	view →
GBM	OS	Tertile	All	0.241	0.518	.030	2	view →
CCRCC	OS	Quartile	III,IV	0.469	0.812	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARFIP2–PDAC (OS)

Open the PDAC breakdown →